• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Philips Respironics has a Class I level ventilators recall

Philips Respironics has a Class I level ventilators recall

August 15, 2023 By Chris Newmarker

Philips logoThe FDA has posted information on its website about another serious recall involving Philips Respironics products.

The news comes the same week that Philips got a vote of confidence from Exor, the investment arm of Italy’s wealthy Agnelli family, which bought a 15% stake in the Dutch medtech giant to become its largest shareholder. Media reports estimate the deal is worth $2.8 billion. Exor gains the right to nominate a member of Philips’ Supervisory Board.

The latest Class I recall covers 73,000 Philips Respironics Trilogy Evo, Evo O2, EV300, and Evo Universal ventilators in the U.S. It’s the Philips subsidiary’s 11th serious recall listed on the FDA’s Medical Device Recalls webpage since 2021 — when a global recall involving millions of CPAPs and other respiratory products with potentially degraded sound abatement foam sidelined Philips from the market.

According to the FDA, Philips initiated the recall of  Trilogy Evo, Evo O2, EV300, and Evo Universal ventilators on March 22 after detecting dust and dirt from the environment in the air path of some devices. Extended exposure to environmental contaminants such as dust and dirt can lead to buildup that may block air vents and cause the device to stop delivering the right amount of air pressure or air volume/flow.

Philips has received 542 reports about the problem, the FDA said. There are currently two reported injuries and one death.

In a statement shared with MassDevice by a Philips spokesperson, the company said it notified the FDA of the potential issue in April and that it immediately informed relevant hospitals and began remediation in May. The FDA posted information about the Class I recall yesterday, but the Class I designation came on June 2. The TGA in Australia has deemed it Class 1, and Health Canada says the recall is Class 2.

The reported death cannot presently be attributed to the potential ventilator problems, according to Philips. “The device related to the patient death report was returned to Philips for investigation, without filters installed, and with severe contamination present. The device operated as intended where numerous high-priority alarms were confirmed.”

Philips also said: “Affected devices may continue to be used in accordance with their instructions for use and the guidance provided by the issued field safety notice. This includes using a particulate filter to prevent accumulation of environmental debris that can cause a device malfunction. Using this filter was previously optional and is now required.”

Filed Under: Featured, Food & Drug Administration (FDA), News Well, Recalls, Regulatory/Compliance, Respiratory Tagged With: Philips, Philips Respironics

More recent news

  • Siemens Healthineers debuts Accela single-breath radiotherapy system
  • GE HealthCare hires chief AI officer from Medtronic
  • Former Teleflex CEO to lead Inspire competitor Nyxoah
  • Retired Stryker leader Tim Scannell dies at 62
  • HighLife raises more than $90M to advance its TMVR system

About Chris Newmarker

Chris Newmarker is the executive editor of WTWH Media life science's news websites and publications including MassDevice, Medical Design & Outsourcing and more. A professional journalist of 18 years, he is a veteran of UBM (now Informa) and The Associated Press whose career has taken him from Ohio to Virginia, New Jersey and, most recently, Minnesota. He’s covered a wide variety of subjects, but his focus over the past decade has been business and technology. He holds bachelor’s degrees in journalism and political science from Ohio State University. Connect with him on LinkedIn or email at [email protected].

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy